C1GALT1 and pancreatic neoplasm: In a study of pancreatic cancer, by using the CRISPR/Cas9 system to disrupt C1GALT1 in human pancreatic ductal adenocarcinomas cells, the results showed enhanced invasiveness and metastatic ability of these cells and increased production of Tn (64).